Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • R-2HG treatment or chemotherapeutic treatment, especially their combinations, decrease MYC levels in leukemic cells (using MONOMAC-6 as a representative). AZA:Azacitidine.

    Cell, 2018, 172(1-2):90-105. Azacitidine purchased from Selleck.

    Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

  • (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

    Dose response curves for azacitidine from 3-5 independent experiments performed in triplicates were generated using GraphPad Prism software. The calculated IC50s are shown.

    Leuk Res, 2018, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PHWFAvOS13MDFOwG0> NWTGWnVNOTJvN{KgbC=> MlTzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M33jPVI3OTN|MkS2
Jurkat  MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWewMlEuPTBizszN M1vKe|EzNTd{IHi= M3HNeYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MV6yOlE{OzJ2Nh?=
CA46 NWDzUpUzTnWwY4Tpc44hSXO|YYm= M3vSZVIxyqEEtV2= MVy0PEBp MmLtbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w M2j6SVI3OTN|MkS2
Raji  NEnad|RHfW6ldHnvckBCe3OjeR?= NEW2OWYyPcLiwsXN MWC0PEBp MmPpbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w NYG0dHFHOjZzM{OyOFY>
Jurkat  MnvuSpVv[3Srb36gRZN{[Xl? MXKzMlXDqML3TR?= MX60PEBp MknQbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w NUXqXmJoOjZzM{OyOFY>
MDA-MB-231 MXvGeY5kfGmxbjDBd5NigQ>? M3XCeVEwOi53L{Wg{txO M2PHflQ5KGh? NHn0TWxl\WO{ZXHz[ZMhfGinIGDUVG4yOiCneIDy[ZN{cW:wIHH0JJRp\SClb37j[ZJvfHKjdHnvckBw\iB3wrFOwG0hPDkEoHi= MYCyOVgyPzJ{OR?=
MDA-MB-231 MX3GeY5kfGmxbjDBd5NigQ>? NULBTHo{OS9{LkWvOUDPxE1? NWHQfoFTPDhiaB?= M4T4Solv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFWtZ4FlcGW{aX6gcXJPSSCjdDD0bIUh[2:wY3XycpRz[XSrb36gc4YhOi53wrFOwG1nd3JiNElCpIg> M{PoN|I2QDF5MkK5
MDA-MB-231 MU\GeY5kfGmxbjDBd5NigQ>? MlTmNU8zNjVxNTFOwG0> Mn3LNlQwPDhiaB?= M2TFe4lv\HWlZYOgJJNq\26rZnnjZY51KFCDUmCgZ4xm[X[jZ3WgZYZ1\XJiNEigbC=> M3vVflI2QDF5MkK5
MCF-7 MVnGeY5kfGmxbjDBd5NigQ>? NGX5XVkyNzJwNT:1JO69VQ>? NET0cZYzPC92ODDo MmH3bY5kemWjc3XzJHBCWlBiY3zlZZZi\2YEoB?= NGHidnYzPThzN{KyPS=>
MDA-MB-231  MmHwSpVv[3Srb36gRZN{[Xl? MUOxM|IvPS93IN88US=> NEX0R5QzPC92ODDo M3\aZolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBucVKQQT2xNlQh[XRidHjlJINwdmOncn70doF1cW:wIH;mJFUh|ryP NHH1d4MzPThzN{KyPS=>
A498 MnnYSpVv[3Srb36gRZN{[Xl? NWHyR3NpOTBiwsXN NIPaZ|g4OiCq MnjjbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u M2nl[lI2PTZ7MEi2
CaKI-2 MnfzSpVv[3Srb36gRZN{[Xl? NEDCTmMyOCEEtV2= M2LO[VczKGh? MnTGbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u M{fyU|I2PTZ7MEi2
Ketr-3 NXjVUGdxTnWwY4Tpc44hSXO|YYm= NEPjUIEyOCEEtV2= NYj4cI5VPzJiaB?= M3juZolv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> M{DOdVI2PTZ7MEi2
A253 NVXpOlRpTnWwY4Tpc44hSXO|YYm= MmGxNVAhyrWP MUWwMVQh\A>? MWXpcoNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBt\X[nbDDv[kB1cGViTUPSxsBi\nSncjCyOEBp NVHDOFljOjV2OEW1N|Y>
A253 NF7zd3FHfW6ldHnvckBCe3OjeR?= M1PNRlExKML3TR?= NUHHNllZPzJiaB?= MX7pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WiCrbjDic5RpKG2nbXLyZY5mKGGwZDDjfZRwe2:uaXOgdJJmeGG{YYTpc45{ NVn3dmxQOjV2OEW1N|Y>
A253 NF63OINHfW6ldHnvckBCe3OjeR?= NEj5VXIyOCEEtV2= MViwMVQh\A>? NI\KNlRz\WS3Y3XzJJRp\SB3LX3leIh6dGO7dH;zbY5mKGOxboTlcpQ> M2PRcFI2PDh3NUO2
PC3 MoH1SpVv[3Srb36gRZN{[Xl? MU[wMlIh|ryPwrC= M1\BflQh\A>? MVfpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 NX7I[VdYOjV2N{ezOFA>
MCF7 M{nTb2Z2dmO2aX;uJGF{e2G7 MXGwMlMh|ryPwrC= MoDKOEBl MXLpcoNz\WG|ZYOgeIhmKGenbnWg[ZhxemW|c3nvckBw\iCLR1\CVFctKFOIUmCxJIFv\CCVTFO2RVE2KGOxbXLpcoVlKHerdHigS3NMOTJ4 MUmyOVQ4PzN2MB?=
PC3 M4DRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfyN3oxNjJizszNxsA> NFfKd|U1KGR? NGe2UVdl\WO{ZXHz[ZMhfGinIHPlcIwh\3Kxd4ToJJRwKDJyLkOlJINwdWKrbnXkJJdqfGhiR2PLNVI3 MmjiNlU1Pzd|NEC=
MCF7 MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPZNXc4OC5|IN88UeKh M33oTVQh\A>? NXjz[VMx\GWlcnXhd4V{KHSqZTDj[YxtKGe{b4f0bEAzPC56JTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> MXOyOVQ4PzN2MB?=
BGC-823 NHzU[mNHfW6ldHnvckBCe3OjeR?= NUiyeJZ5PcLizszN MXO3NkBp MmHT[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NXnrO2VEOjV2N{W3N|M>
MKN28 Ml3BSpVv[3Srb36gRZN{[Xl? MX:1xsDPxE1? MV:3NkBp MmfF[IVkemWjc3XzJJRp\SCSUlytN{Bxem:2ZXnuJIxmfmWuIIPp[45q\mOjboTsfS=> NFXwNFMzPTR5NUezNy=>
SGC-7901 MYjGeY5kfGmxbjDBd5NigQ>? NEH3UGU2yqEQvF2= M4HJ[lczKGh? NVnOdGo{\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? M2TnUVI2PDd3N{Oz
MKN45 NW\p[W1MTnWwY4Tpc44hSXO|YYm= NHS4d3M2yqEQvF2= NW\INXA2PzJiaB?= MXXk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 M2TB[FI2PDd3N{Oz
BGC-823 NGfmbXdHfW6ldHnvckBCe3OjeR?= NXLPcGptPcLizszN M2\HTlczKGh? MY\k[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 Mon5NlU1PzV5M{O=
MKN28 NV7CU|VoTnWwY4Tpc44hSXO|YYm= NWHlRZJWPcLizszN NFnDS|c4OiCq MmTj[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= M1jycVI2PDd3N{Oz
SGC-7901 M{fafGZ2dmO2aX;uJGF{e2G7 NFuydWE2yqEQvF2= MoXpO|IhcA>? MlfK[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= MU[yOVQ4PTd|Mx?=
MKN45 MWDGeY5kfGmxbjDBd5NigQ>? M3v2XVXDqM7:TR?= M{\HWlczKGh? MWTk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 M3jKclI2PDd3N{Oz
HREC MWDGeY5kfGmxbjDBd5NigQ>? NILqNZM2NzFywrFOwG0> NXzFeIFmPDhiaB?= NUPwSHFTcW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFzVSnkzPTN3Mke0Oy=>
HRPE NIPxSG9HfW6ldHnvckBCe3OjeR?= NF[z[VI2NzFywrFOwG0> NHrxXJM1QCCq NUXQPYh1cW6mdXPld{BRTUSIIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWf6UnM2OjV|NUK3OFc>
HREC MUjGeY5kfGmxbjDBd5NigQ>? NVHpRoQ1PS9zMNMg{txO NVjRfItyPDhiaB?= M2PyXIRwf25vcnXneYxifGW|IH;mJHZGT0ZuIFnDRW0uOSBqbn;0JJBzd3SnaX6gcIV3\WxiaX6gTHJRTSClZXzsd{ktKEmOLUJOtkBld3OnLXTldIVv\GWwdHz5 M3jnZVI2OzV{N{S3
HRPE Mnu1SpVv[3Srb36gRZN{[Xl? MmrNOU8yOMLizszN NFPwbZI1QCCq MVfkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk> MlPDNlU{PTJ5NEe=
MSCs NEPLNYZHfW6ldHnvckBCe3OjeR?= Ml;RNVAh|ryP MmfKNlQhcA>? NVrrfXNJeHKxbX;0[ZMhfGinIHPvcY1qfG2nboSgc4YhVVOFczD0c{BugW:lYYLkbYFtKGSrZn\ldoVvfGmjdHnvci=> M4\MTlI2OzVzM{m1
HL-60 NVnUSVNkTnWwY4Tpc44hSXO|YYm= MX:1JO69VQ>? MoP5O|IhcA>? MoHBSG1UVw>? NEXnS5F{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO|aX;u MmHnNlU{OTlyNEm=
MV4-11 M4HIS2Z2dmO2aX;uJGF{e2G7 NWS5O2ZYPSEQvF2= M1;WNlczKGh? M3vhbGROW09? M37kW5Nq\26rZnnjZY51dHlidYDy[Yd2dGG2ZYOgXm5HOzh{IHX4dJJme3Orb36= MmPiNlU{OTlyNEm=
A2780 NEPiO49HfW6ldHnvckBCe3OjeR?= MWm1JOK2VcLi NUXqSVZ{PyCm NXXMWplqcW6lcnXhd4V{KESQQTDt[ZRpgWyjdHnvckBt\X[nbB?= MojCNlUzQTl4OUS=
CP70 M3jER2Z2dmO2aX;uJGF{e2G7 NYXOdYNVPSEEtV5CpC=> MX[3JIQ> MmPYbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>? M3zuWVI2Ojl7Nkm0
A2780 MoOwSpVv[3Srb36gRZN{[Xl? NXvFPWIyPSEEtV5CpC=> NFnKUW04KGR? NVrIT45Lf2Wja3Xud{B1cGVibHX2[Ywhd2ZibXX0bJlt[XSrb36= M2\ndlI2Ojl7Nkm0
CP70 NHPFbpJHfW6ldHnvckBCe3OjeR?= M{\TW|UhyrWPwrC= M1m5SVch\A>? MVn3[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? M{jrXVI2Ojl7Nkm0
OCM3 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVmwMlUwOS9{IN88US=> MYS3JIQ> MUTEUXNQ M1XVUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3P4TFI2OTR4OUix
92.1 NGHlW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6wMlUwOS9{IN88US=> MmjQO{Bl NInOZphFVVOR M1\ZZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NVXoc2d5OjVzNE[5PFE>
OCM1 NV\Bepk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle1NE42NzFxMjFOwG0> MkK2O{Bl MUXEUXNQ MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M{HCVVI2OTR4OUix
OMM1 NXLaWGd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTyNE42NzFxMjFOwG0> MVS3JIQ> MWXEUXNQ NVvKOJNFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NEHXZ2czPTF2Nkm4NS=>
Mel 285 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLSNE42NzFxMjFOwG0> M1zlXlch\A>? MkDsSG1UVw>? M3zteolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NVjvVIdwOjVzNE[5PFE>
Mel 290 M3\reWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:zeVAvPS9zL{Kg{txO M{nPN|ch\A>? MXjEUXNQ MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MkPVNlUyPDZ7OEG=
OCM3 MUDGeY5kfGmxbjDBd5NigQ>? NU\veG91OC53L{Gg{txO MXK0PEBp NHy5[WpFVVOR NXTHeIxX\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= NVrz[WU1OjVzNE[5PFE>
92.1 NFPrN4NHfW6ldHnvckBCe3OjeR?= NFXjZlgxNjVxMTFOwG0> NUXrOWhFPDhiaB?= NXTOV4JGTE2VTx?= MV\k[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 MXqyOVE1Pjl6MR?=
OCM1 Mn7XSpVv[3Srb36gRZN{[Xl? MUCwMlUwOSEQvF2= NVu2bpFMPDhiaB?= M1LEV2ROW09? MnnB[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MnnvNlUyPDZ7OEG=
OMM1 NH;4U|FHfW6ldHnvckBCe3OjeR?= NGjMTZMxNjVxMTFOwG0> MX20PEBp MYLEUXNQ MlP0[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NUjwdY46OjVzNE[5PFE>
Mel 285 NYDWd|JNTnWwY4Tpc44hSXO|YYm= NEOyenQxNjVxMTFOwG0> MUm0PEBp MmXMSG1UVw>? Mo\t[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MlLQNlUyPDZ7OEG=
Mel 290 NYm2RVd1TnWwY4Tpc44hSXO|YYm= MUewMlUwOSEQvF2= NVLkTnpoPDhiaB?= NUnmfGFtTE2VTx?= MYTk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 NXSwUohWOjVzNE[5PFE>
OCM3 NWDsNlJJTnWwY4Tpc44hSXO|YYm= NHriUoIxNjVxMTFOwG0> MWS0PEBp NYTRVW5HTE2VTx?= M4fXOYRm[3KnYYPld{Bqdn[jc3nvckBld3OnIHTldIVv\GWwdHz5xsA> M3LBfFI2OTR4OUix
Mel 290 MoDtSpVv[3Srb36gRZN{[Xl? M33Qb|AvPS9zIN88US=> NX;0eJljPDhiaB?= NFvoWW5FVVOR NVjZcY9P\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? NVPvUYtoOjVzNE[5PFE>
OMM1 NETGSW1HfW6ldHnvckBCe3OjeR?= MXSwMlUwOSEQvF2= MW[0PEBp NXPO[FBQTE2VTx?= NXKzVXA3\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? M{XXTFI2OTR4OUix
OCM1 MkjBR4VtdCCYaXHibYxqfHliQYPzZZk> MoXmNE42NzFizszN M1XoVVUh\A>? NXywfVNvTE2VTx?= M3ruVYRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u MVeyOVE1Pjl6MR?=
92.1 MnLuR4VtdCCYaXHibYxqfHliQYPzZZk> MoL2NE42NzFizszN MnPBOUBl MnXGSG1UVw>? M1\qZYRm[3KnYYPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuII\pZYJqdGm2eTDpcohq[mm2aX;u M322S|I2OTR4OUix
OCM1 NFHwSlZHfW6ldHnvckBCe3OjeR?= M17RTlAvPS9zIN88US=> NH\OUWQ1QCCq M1PBdGROW09? MnzXZ4F2e2W|IHfsc4JidCCGTlGgbJlxd22ndHj5cIF1cW:wIHH0JGwuOSC{ZYDlZZQhdG:laR?= MmToNlUyPDZ7OEG=
OCM3 MlnYSpVv[3Srb36gRZN{[Xl? NW\JNGRxOC53L{Gg{txO MnjMOFghcA>? NUjlb|FKTE2VTx?= M1jFXINifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= MlrINlUyPDZ7OEG=
92.1 NWfqNZhtTnWwY4Tpc44hSXO|YYm= MYKwMlUwOSEQvF2= NXnGUY5jPDhiaB?= NWL6TXVMTE2VTx?= NVnqRnpM[2G3c3XzJIdtd2KjbDDEUmEhcHmyb33leIh6dGG2aX;uJIF1KExvMTDy[ZBm[XRibH;jbS=> M2q1clI2OTR4OUix
IMR32 MUfGeY5kfGmxbjDBd5NigQ>? MWqzJO69VQ>? M321SlczKGh? Mmi0SG1UVw>? M4HSS4lv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> Ml32NlUyODR6NUC=
IMR5-75 MW\GeY5kfGmxbjDBd5NigQ>? MV:zJO69VQ>? M3zI[lczKGh? NFjkd2RFVVOR NWDvTnB7cW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 NEDreXMzPTFyNEi1NC=>
Be(2)-C MoLOSpVv[3Srb36gRZN{[Xl? MXezJO69VQ>? MXW3NkBp NH;YZpFFVVOR MX3pcoR2[2W|wrDwNVkuUU6NNHVCpIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= M1ryUlI2OTB2OEWw
Bxpc-3 NYXJTGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjOU8yOCEQvF2= M1H5ZVI1NzR6L{eyJIg> MWXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBDgHClLUOgZ4VtdHNiaX6geIlu\S1iYX7kJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5menN? MY[yOVA3OTd|MR?=
Bxpc-3 MWnBdI9xfG:|aYOgRZN{[Xl? MkHwOU8yOCEQvF2= MljLNlQwPDhxN{KgbC=> NVrjfYRPcW6mdXPld{BieG:ydH;zbZMhcW5idHnt[U0h[W6mIHPvcoNmem62cnH0bY9vKG2jbn7ldpM> MoPLNlUxPjF5M{G=
Bxpc-3 NXj2NZl4TnWwY4Tpc44hSXO|YYm= M1f5WFUwOTBizszN M3;4c|I1NzR6L{eyJIg> MnrP[IVkemWjc3XzJO6zNWOjdHXubY4h\XiycnXzd4lwdiCjZoTldkAzPCCq M4TrXVI2ODZzN{Ox
Bxpc-3 M{GyOmZ2dmO2aX;uJGF{e2G7 MmX2OU8yOCEQvF2= MWKyOE81QC95MjDo NX:zN4Q{\GWlcnXhd4V{KGO7Y3zpcmQyKGW6cILld5Nqd25iYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDFyIN88US=> M4PwZ|I2ODZzN{Ox
Bxpc-3 NGHs[o9HfW6ldHnvckBCe3OjeR?= M3vUXlUwOTBizszN M4Xmb|I1NzR6L{eyJIg> NEDBVJlld3ewLYLl[5Vt[XSnUzDjMY16[yCvUl7BJIV5eHKnc4Ppc44hcW5idHnt[U0h[W6mIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldpM> Ml\5NlUxPjF5M{G=
HL-60 NGiyN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;DNU4xKM7:TR?= MlvQOFghcA>? MUnzbYdvcW[rY3HueIx6KGmwaHnibZR{KEiOLU[wJINmdGxiZ4Lve5RpyqB? M2HrOlI2ODVzMUG5
HL-60 MWLGeY5kfGmxbjDBd5NigQ>? M4LwXlEvOCEQvF2= MoHiOFghcA>? NF\3OIlqdmO{ZXHz[ZMheDJzV1HGNU9EUVBzwrDhcoQh[2G|cHHz[U0{KGW6cILld5Nqd28EoB?= M37V[VI2ODVzMUG5
HL-60 NE\QdGRHfW6ldHnvckBCe3OjeR?= NFjXTGEyNjBizszN NXXRWZM6PDhiaB?= NXrZWWpT\GWlcnXhd4V{KEKlbD34UEBmgHC{ZYPzbY9vyqC|aXfubYZq[2GwdHz5 NYKwcVNUOjVyNUGxNVk>
HuTu-80  NUHje4ZUTnWwY4Tpc44hSXO|YYm= MX6xM|UwOTBizszN MWC0PE84OiCq MWTpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gbJVu[W5iTmDDNWwyKG2UTlGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M1nSeFI1QTB2ME[y
Caco2  MXjGeY5kfGmxbjDBd5NigQ>? MWGxNEDPxE1? M2HTe|Q5KGh? M3vncYlv[3KnYYPld{BPWENzTEGg[ZhxemW|c3nvci=> NYD1bnFxOjR7MESwOlI>
HepG2  M2PGV2Z2dmO2aX;uJGF{e2G7 NULwSHg4OC1{NTFOwG0> NWTS[mpvOjRiaB?= NELl[5Zl\WO{ZXHz[ZMhe3WkdHnsbZNqdi:tZYjpckB1gXCnIEmgLHBEW0t7KTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6 M17sUlI1QDV3NkS2
HepG2  MVTGeY5kfGmxbjDBd5NigQ>? M3PqdFAuOjVizszN NGXWb2QzPCCq MVnpcoNz\WG|ZYOgcI94KGSnboPpeJkhdGmyb4Dyc5RmcW5icnXj[ZB1d3JiKFzEUHIqKGenbnWg[ZhxemW|c3nvcuKh MmPVNlQ5PTV4NE[=
HepG2  M1;ONWZ2dmO2aX;uJGF{e2G7 NH:3c3oyOCEQvH5CpC=> MlW5NE0zPCCq M1LteoRm[3KnYYPld:KhWEOVS{pCpIFv\MLiSF3HR3LDqGW6cILld5Nqd25iYX7kJIlv[3KnYYPld{BNTEyUIHX4dJJme3Orb36gZYZ1\XJiNjDo MkXTNlQ5PTV4NE[=
HepG2  M{f3Z2Z2dmO2aX;uJGF{e2G7 NVrQXWhuOTBizszt M1X6NVI1KGh? MVXwdo9ud3SnczDjfZRwe2:uaXOgcoV2fHKjbDDsbZBq\CCjY3P1cZVt[XSrb36gbY5l\XCnbnTlcpRtgSCxZjDlfI9o\W6xdYOgcIlxd3C{b4TlbY5{ NYTROIZSOjR6NUW2OFY>
HepG2  NVj4dI95TnWwY4Tpc44hSXO|YYm= MVSxNEDPxG1? NHjwdmEzPCCq M1:5SJBz\X[nboTzJHNTTUKSIIDyc4Nme3Orbne= MYSyOFg2PTZ2Nh?=
HC45  M1vMSGZ2dmO2aX;uJGF{e2G7 M320S|XDvU4EoB?= NEPxfJA1KGR? MYXy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? M4TiNFI1PzZ{OEC5
CNDT2  M3fNdWZ2dmO2aX;uJGF{e2G7 NVzhR4VkPcL3TdMg M2m5eFQh\A>? MYLy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? NIPsNXIzPDd4MkiwPS=>
CNDT2  MmXtSpVv[3Srb36gRZN{[Xl? MXe1xtVOyqB? MWG0JIQ> MYfpcoNz\WG|ZYOg[4Vv\SCneIDy[ZN{cW:wIH;mxsBYUUZzLDDQNVYtKEOGSEGsxsBNSU2DMT|CpIFv\MLiQ2TOUmIy MYeyOFc3OjhyOR?=
T-cells MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO1M|IxKM7:TR?= MoK1NE01QCCq NHflNpZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NHr1Tm4zPDd3N{K4Ny=>
CD3+ T-cells MYHGeY5kfGmxbjDBd5NigQ>? NE\SeHE2NzJyIN88US=> MX20PEBp NV3INm9SfXC{ZXf1cIF1\XNicEG1JIV5eHKnc4Ppc44> Mom3NlQ4PTd{OEO=
CD4+ T-cells MWPGeY5kfGmxbjDBd5NigQ>? Mlu1OU8zOCEQvF2= MYi0PEBp NHPJUXl2eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> M3TQN|I1PzV5Mkiz
CD8+ T-cells NIr4dZlHfW6ldHnvckBCe3OjeR?= Mn[1OU8zOCEQvF2= M{HCfVQ5KGh? MVH1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= NXvzPVBLOjR5NUeyPFM>
CD3+ T-cells NX;jZlduTnWwY4Tpc44hSXO|YYm= NHvST5I2NzJyIN88US=> NYXIe3UyPDhiaB?= NIDuNGR2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCIT2jQNy=> MVqyOFc2PzJ6Mx?=
CD4+ T-cells MY\GeY5kfGmxbjDBd5NigQ>? NWXuOI1nPS9{MDFOwG0> MV20PEBp NXrlSYczfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiRl;YVFM> M3uwOFI1PzV5Mkiz
CD4+ T-cells MlzwSpVv[3Srb36gRZN{[Xl? M173[VUwOjBizszN MUK0PEBp NI\0VoZz\WS3Y3XzJHRDTVRzwrDtVm5CKGW6cILld5Nqd25? NGXjO3gzPDd3N{K4Ny=>
CD4+ T-cells NUTmd4k5TnWwY4Tpc44hSXO|YYm= MleyOU8zOCEQvF2= MWe0PEBp M2LoXJVxemWpdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nyqCUT2NOt5TDqA>? NX;iZ2FjOjR5NUeyPFM>
CD4+ T-cells NUHITXQxTnWwY4Tpc44hSXO|YYm= MlO4OU8zOCEQvF2= NEPWcZo1QCCq NUP6PYZEcW6qaXLpeJMhdWWvb4L5JHQu[2WubIO= NH7o[pgzPDd3N{K4Ny=>
CD8+ T-cells NWH2UIxNTnWwY4Tpc44hSXO|YYm= Ml\COU8zOCEQvF2= NITSZYg1QCCq MnjEbY5pcWKrdIOgcYVud3K7IGStZ4VtdHN? NITncVEzPDd3N{K4Ny=>
CD3+ T-cells M3vKZWZ2dmO2aX;uJGF{e2G7 NIHHbFU2KM7:TR?= NXu2OoF1PDhiaB?= M4DK[5Jm\HWlZYOgcI9v\y22ZYLtJI1mdW:{eTDj[YxtKHCqZX7veJlx\Q>? NGO2[mMzPDd3N{K4Ny=>
U937 NGXhRVNCeG:ydH;zbZMhSXO|YYm= NWG2SHJsOTBizszN NFL5fFQ4OiCq NFHWPJpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 NEDlTJEzPDZ6MEi2OS=>
HL-60 MVfBdI9xfG:|aYOgRZN{[Xl? MV:xNEDPxE1? NGPPOFk4OiCq NXnnfYdKcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= M3XQXVI1PjhyOE[1
MCF7 M3P5PWZ2dmO2aX;uJGF{e2G7 NEGwRnQ2KM7:TR?= NUf3fZUzPDhiaNMg M{nucYRqe3CuYYnzJJNmdGWldHn2[UB1d3irY3n0fUB1d3ejcnSgd5V{eGWwZHXkJG1ETi15IHPlcIx{ MkmzNlQ3OzN|NUC=
MCF7 NEjEWWhHfW6ldHnvckBCe3OjeR?= MX:xNEDPxE1? NF3GRYMzPCCqwrC= M{Kxdolv\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2ViNzDhcoQhWEGUUNMg NYLCXpZ2OjR4M{OzOVA>
MCF7 MWTGeY5kfGmxbjDBd5NigQ>? MlHVNQKBmzBwNTFOwG3DqA>? MnjXO{Bl NF3YdYtqdmirYnn0d{B1cGViZ4Lve5RpKE2FRj23JJR2dW:{c4Do[ZJmeyCrbjDzeZNx\W6|aX;uJIN2dHS3cnXzxsA> MXyyOFY{OzN3MB?=
MCF7 MmjISpVv[3Srb36gRZN{[Xl? M1TleVAvPSEQvF5CpC=> MnrZNVQh\A>? MnyydoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI> NFPaNFEzPDZ|M{O1NC=>
MCF7 M1vyfmZ2dmO2aX;uJGF{e2G7 MWKwMlA26oDVMkCg{txO NUPLNYhSOSCm NHTGPYtz\WS3Y3XzJJRp\SClbH;uZYwhe3W{dnn2ZYwhd2ZiTVPGMVch[2WubIOgbY4hdW:wb3zhfYVzKGO3bIT1doV{ Mlj6NlQ3OzN|NUC=
T47D  MoLUSpVv[3Srb36gRZN{[Xl? MmPMNE42KM7:TR?= MkXPOEBl MnnYbY5pcWKrdIOgeJVud3K|cHjldoUh\m:{bXH0bY9v M{DCeFI1PjN|M{Ww
MCF7 NIDTZVVHfW6ldHnvckBCe3OjeR?= M3;S[VAvPeLCk{GwJO69VQ>? M17G[VQ5KGkEoB?= MULpcohq[mm2czD0bIUh\2GyIHPsc5N2emViaX6geIhmKHexdX7kJIhm[WyrbnegZZN{[Xl? M33PTlI1PjN|M{Ww
MCF7 MX7GeY5kfGmxbjDBd5NigQ>? M4\pUFAwOTBizszN MXSyOEBp NFLDfotqdmirYnn0d{B1cGViYXP0bZZqfHlib3[gUW1RQQ>? NG\aO4szPDZ|M{O1NC=>
MDA-MB-231  NVK1[JR5TnWwY4Tpc44hSXO|YYm= M2r5WVAvPeLCk{GwJO69VQ>? M3nvU|M3KGh? NVvxUGV2cW6qaXLpeJMhfGinIH3p[5JifGmxbh?= NXzVNmc5OjR4M{OzOVA>

... Click to View More Cell Line Experimental Data
In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing. 		10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5
CAS No. 320-67-2
Storage powder
in solvent
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03862157 Not yet recruiting Acute Myeloid Leukemia|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Eosinophilic Leukemia Not Otherwise Specified|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Dysplasia|Essential Thrombocythemia|FGFR1 Gene Rearrangement|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm Unclassifiable|Myeloid Neoplasm|Myeloproliferative Neoplasm|Myeloproliferative Neoplasm Unclassifiable|Overt Primary Myelofibrosis|PDGFRA Gene Rearrangement|PDGFRB Gene Rearrangement|Polycythemia Vera|Polycythemia Vera Post-Polycythemic Myelofibrosis Phase|Prefibrotic/Early Primary Myelofibrosis M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Phase 1|Phase 2
NCT03628209 Not yet recruiting Osteosarcoma|Osteosarcoma in Children|Osteosarcoma Recurrent|Sarcoma H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb May 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

selleck catalog

DNA Methyltransferase Signaling Pathway Map
Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID